<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176121</url>
  </required_header>
  <id_info>
    <org_study_id>OXY16-TW-401</org_study_id>
    <nct_id>NCT03176121</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain</brief_title>
  <acronym>STOP Pain</acronym>
  <official_title>A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Mundipharma Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Mundipharma Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and tolerability of oxycodone control-released (CR)
      and/or immediate-released (IR) use in patients with moderate to severe cancer pain in a
      3-months period in Taiwan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, long-term study carrying in multi-centers. Around 200 patients with
      moderate to severe cancer pain (NRS ≥ 4) who agreed and signed informed consent will be
      enrolled to receive oxycodone with continuous around-the-clock pattern. The study is to
      evaluate the safety and tolerability of cancer patients who receive CR and/or IR oxycodone.
      The number and percentage of patients with adverse events and serious adverse events will be
      recorded throughout the study.

      The study will continue for 3 months to observe the safety and tolerability. After screening
      at Screening visit, patients begin the study by the first day visit (Day 1). Pain assessment,
      study related questionnaires are giving out to measure the baseline scale of each patient.
      Questionnaires including rate of quality of analgesia, EQ-5D and clinical opiate withdrawal
      scale (COWS). The prescription of the study drug will be recorded from Day 1. Patients will
      need to visit bi-weekly, including Wk 2 (Day 14±3), Wk 4 (Day 28±3), Wk 6 (Day 42±3), Wk 8
      (Day 56±3), Wk 10 (Day 70±3) and Wk 12 (Day 84±3). Pain assessment will be assessed in each
      visit, drug accountability will be recorded accordingly. The rate of quality of Analgesia
      will be assessed in each visit; QoL (EQ-5D) will be recorded in Wk 4, Wk 8 and Wk 12. The
      COWS will be assessed again in Wk 12.

      The safety for individual patient will be followed during study up to 2 weeks after the end
      of treatment (EOT) or early termination (ET). The telephone contact for safety follow-up is
      acceptable for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of patients with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <description>Number and percentage of patients with adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pain intensity scale (NRS)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The change from baseline pain intensity scale (NRS) to each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (days) needs in first titration to a stable dose</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The time (days) needs in first stable titration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average dosage (mg/day) needs in first titration to a stable dose</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The average dosage needs in first stable titration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of analgesia using rating of excellent, very good, good, fair or poor</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The percentage of patients rating quality of analgesia of excellent, very good, good, fair or poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment discontinuation reason (due to AE, withdraw consent, or any kinds of reasons)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Analysis treatment discontinue reason (due to AE, withdraw consent, or any kinds of reasons)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QoL questionnaire (EQ-5D)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The change from baseline in QoL questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opiate withdrawal level by Clinical Opiate Withdrawal Scale (COWS)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The change of clinical opiate withdrawal scale (COWS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (PE and vital sign change from baseline)</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <description>The change from baseline in PE and vital sign</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Oxycodone treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose.
After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.</description>
    <arm_group_label>Oxycodone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cancer patients aged 20 years old and over

          2. ECOG ≤ 2

          3. Moderate to severe pain intensity (NRS pain score ≥ 4)

          4. Cancer-related pain that requires treatment with continuous around-the-clock strong
             opioid analgesic

          5. Patients who will not be treated with radiotherapy within 7 days prior to screening
             and during study

          6. Patients or his/her caregivers who are able to fill out the questionnaire forms

          7. Patient provided signed informed consent

        Exclusion Criteria:

          1. Patients diagnosed with non-cancer pain or unexplained pain

          2. Patients who cannot be applicable for oral administration

          3. Patients who have constipation (CTCAE grade 3 and above)

          4. Patients with evidence of significant structural/functional abnormalities of GI tract
             or planned to undergo surgeries that have high risk lead to gastrointestinal stenosis,
             blind loop or gastrointestinal obstruction during study

          5. Abnormal lab results, with obvious clinical significance, such as the creatinine ≥ 2
             fold of upper limit of normal value, or ALT or AST ≥ 2.5 fold of upper limit of normal
             value (≥ 5 fold, to the patients with liver metastasis or primary liver cancer), or
             liver function of Child C grade prior to study

          6. Pregnant or nursing (lactating) women

          7. Patients who are drug or alcohol abuse

          8. Patients with moderate to severe psychiatric problems

          9. Patients who have hypersensitivity to oxycodone

         10. Patients who are clinically unstable or have a life expectancy of less than three
             months making completion of the trial unlikely
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brook Chung, MSc</last_name>
    <phone>886-2-87297521</phone>
    <email>brook.chung@mundipharma.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Chang-hua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Lin Ho, PhD</last_name>
      <phone>886-975-786-818</phone>
      <email>Drho123@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ming-Lin Ho, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pei-Yu Tsai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsuan-Yu Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Yuan Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guan-Min Lai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Chiayi branch</name>
      <address>
        <city>Chiayi County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Shih Huang, PhD</last_name>
      <phone>886-5-3621000</phone>
      <phone_ext>2862</phone_ext>
      <email>WSHuang77@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Wen-Shih Huang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Chien Chin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Hung Kuo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meng-Chiao Hsieh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Yi Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Jung Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsan-Hung Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng-Che Kuan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung branch</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien-Chang Lu, MD</last_name>
      <phone>886-7-7317123</phone>
      <phone_ext>8008</phone_ext>
      <email>cclu999@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chien-Chang Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong-Hwa Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Lo Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wang-Hseng Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ko-Chao Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai-Lung Tsai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yueh-Ming Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Li Su, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tai-Jan Chiu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eng-Yen Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsuan-Chih Hsu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Keelung branch</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Ko Tseng, MD</last_name>
      <phone>886-24313131</phone>
      <phone_ext>2624</phone_ext>
      <email>tsangwen@cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Wen-Ko Tseng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chung-Wei Fan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang-Chih Liu, PhD</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>1639</phone_ext>
      <email>dr0363@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Liang-Chih Liu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hwei-Chung Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Jung Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao-Chung Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Ching Lin, PhD</last_name>
      <phone>886-4-23592525</phone>
      <phone_ext>5613</phone_ext>
      <email>jclin@mail.vghtc.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Jin-Ching Lin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Li Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin-Wei Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chieh-Lin Teng, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shao-Min Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Chun Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Fang Chang, PhD</last_name>
      <phone>886-2-25433535</phone>
      <phone_ext>3455</phone_ext>
      <email>changyifang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yi-Fang Chang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caleb Gon-Shen Chen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johnson Lin, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ken-Hong Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Cheng Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia-Mo Lin, MD</last_name>
      <phone>886-2-28332211</phone>
      <phone_ext>2030</phone_ext>
      <email>M002178@ms.skh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chia-Mo Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Yu-Wung Yeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shang-Jyh Kao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiunn-Song Jiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Liang Ho, MD</last_name>
      <phone>886-2-87927208</phone>
      <email>hochingliang@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Ching-Liang Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, LinKou branch</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinn-Shiun Chen, MD</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>2101</phone_ext>
      <email>chenjs@adm.cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Jinn-Shiun Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rei-Ping Tang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yau-Tong You, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jy-Ming Chiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pao-Shiu Hsieh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien-Yuh Yeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Sy Tsai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shin-Yuan Hung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeng-Fu You, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sum-Fu Chiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Chou Lai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsai-Sheng Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Chih Hsu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009 Aug;20(8):1420-33. doi: 10.1093/annonc/mdp001. Epub 2009 Feb 24.</citation>
    <PMID>19244085</PMID>
  </reference>
  <reference>
    <citation>Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012 Feb;13(2):e58-68. doi: 10.1016/S1470-2045(12)70040-2. Review.</citation>
    <PMID>22300860</PMID>
  </reference>
  <reference>
    <citation>Ahmedzai SH, Leppert W, Janecki M, Pakosz A, Lomax M, Duerr H, Hopp M. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015 Mar;23(3):823-30. doi: 10.1007/s00520-014-2435-5. Epub 2014 Sep 14.</citation>
    <PMID>25218610</PMID>
  </reference>
  <reference>
    <citation>Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007 Jul;61(7):1181-7. Epub 2007 May 4. Review.</citation>
    <PMID>17488292</PMID>
  </reference>
  <reference>
    <citation>Mueller-Lissner S. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther. 2010 Sep;27(9):581-90. doi: 10.1007/s12325-010-0057-y. Epub 2010 Aug 11. Review.</citation>
    <PMID>20714946</PMID>
  </reference>
  <reference>
    <citation>Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer. 1998 Jul;6(4):356-64. Review.</citation>
    <PMID>9695203</PMID>
  </reference>
  <reference>
    <citation>Kalso E. Oxycodone. J Pain Symptom Manage. 2005 May;29(5 Suppl):S47-56. Review.</citation>
    <PMID>15907646</PMID>
  </reference>
  <reference>
    <citation>Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep. 2010 Jul-Aug;62(4):578-91. Review.</citation>
    <PMID>20884999</PMID>
  </reference>
  <reference>
    <citation>Stessel B, Theunissen M, Fiddelers AA, Joosten EA, Kessels AG, Gramke HF, Marcus MA. Controlled-release oxycodone versus naproxen at home after ambulatory surgery: a randomized controlled trial. Curr Ther Res Clin Exp. 2014 Nov 28;76:120-5. doi: 10.1016/j.curtheres.2014.10.001. eCollection 2014 Dec.</citation>
    <PMID>25516773</PMID>
  </reference>
  <reference>
    <citation>Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage. 1999 Oct;18(4):271-9.</citation>
    <PMID>10534967</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxycodone</keyword>
  <keyword>Cancer Pain</keyword>
  <keyword>Long-term use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

